Company intelligence / Profile preview

Taliram

San Carlos, California, United Stateselementaryeducation.tripura.gov.in ↗

Ownership: Private
Development stage: Other

Overview

Talima Therapeutics has developed a proprietary micro implant drug delivery platform designed to enable site-specific administration of small molecule drugs, aiming to reduce systemic side effects. Its lead program targets onychomycosis and was in phase I/II clinical trials as of 2008. The company raised $19 million Series B funding in 2007 to advance through Phase II trials.[1][5] No recent clinical results are available.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Small moleculeMicro implant drug delivery technology
Industry: Biotech

Partnerships

US Venture PartnersLatterell Venture PartnersDe Novo VenturesPalo Alto Healthcare—investors with board involvement rather than commercial partnerships.

Beyond the preview

Go deeper on Taliram.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taliram.

Explore the full profile